About CARVYKTI®
How CARVYKTI® works
Manufacturing CARVYKTI®
CARVYKTI® Efficacy
CARTITUDE-4
Primary Analysis
Study Design
Progression-Free Survival (PFS)
Overall Survival (OS)
Depth of Response
Duration of Response (DOR)
CARTITUDE-4
Follow-Up Analysis
Progression-Free Survival (PFS)
Overall Survival (OS)
Depth of Response
Duration of Response (DOR)
Time to Next Treatment (TTNT)
CARTITUDE-1
Primary Analysis
Study Design
Depth of Response
Duration of Response (DOR)
Time to Response
CARTITUDE-1
5-Year Follow-Up Analysis
5-Year Baseline Characteristics
5-Year Duration of Response
CARVYKTI® Safety
Boxed Warning
Cytokine Release
Syndrome (CRS)
Neurologic Toxicities
Hemophagocytic
Lymphohistiocytosis (HLH)
Prolonged and/or
Recurrent Cytopenias
Immune Effector Cell-Associated Enterocolitis
Secondary Malignancies
Additional Warnings & Precautions, and ARs ≥10%
Safety Timeline/Long-Term Safety
Treatment Process
Patient Identification
Steps in the Treatment Process
Resources
For Physicians
For Nurses and APPs
For Patients and Care Partners
Patient Support Program
For Access and Reimbursement Support
For Order Management
Support for Nurses & APPs
Urgency to Treat Earlier
Attrition Rates
T-cell Fitness and Bridging Therapy
Treatment Centers
Coverage Lookup
Get In Touch
CARVYKTI® Prescribing Information
FAQs
Contact Us
Go To Patient Website
Prescribing Information
CARVYKTI® PRESCRIBING INFORMATION
CARVYKTI® LA INFORMACIÓN DE PRESCRIPCIÓN
Get In Touch
FAQs
Contact Us
For US Healthcare Professionals
Go To Patient Website
Treatment Centers
Coverage Lookup
